It is made available under a CC-BY-NC-ND 4.0 International license .

1 [Title Page]

## 2 Performance of the Verily Study Watch for Measuring Sleep Compared to

- 3 Polysomnography
- 4
- 5 **Authors**: Sohrab Saeb, PhD<sup>1</sup>\*; Benjamin W. Nelson, PhD<sup>1, 2</sup>\*; Poulami Barman, MS<sup>1</sup>; Nishant
- 6 Verma, PhD<sup>1</sup>; Hannah Allen, BS<sup>1</sup>; Massimiliano de Zambotti, PhD<sup>3</sup>; Fiona C. Baker, PhD<sup>3</sup>;
- 7 Nicole Arra, BA<sup>3</sup>; Niranjan Sridhar, PhD<sup>1</sup>; Shannon S. Sullivan, MD, MSc<sup>1, 4</sup>; Scooter Plowman,
- 8 MD, MBA, MHSA, MSc<sup>1</sup>; Erin Rainaldi, MS<sup>1</sup>; Ritu Kapur, PhD<sup>1, 5</sup>; Sooyoon Shin, PhD<sup>1</sup>

#### 9 Affiliations:

- 10 <sup>1</sup>Verily Life Sciences, South San Francisco, CA, United States
- <sup>2</sup>Division of Digital Psychiatry, Department of Psychiatry, Harvard Medical School and Beth
   Israel Deaconess Medical Center, Boston, MA, United States
- <sup>3</sup>Center for Health Sciences, SRI, Menlo Park, California, USA, United States
- <sup>4</sup>Division of Pulmonary, Asthma, and Sleep Medicine, Department of Pediatrics, Stanford
   University School of Medicine, Palo Alto, CA, United States
- <sup>5</sup>Department of Neurology, Radboud University Medical Center, Nijmegen, Netherlands
- 17 \*These authors contributed equally to this work, first authorship shared
- 18

## 19 Corresponding Author:

- 20 Sohrab Saeb, PhD
- 21 Verily Life Sciences
- 22 279 E Grand Ave, South San Francisco, CA 94080
- 23 P. 650-495-7100
- 24 Email: <u>sosata@verily.com</u>
- 25
- 26 Keywords: Sleep-wake detection; sleep stage; digital health measures; polysomnography; free-
- 27 living; sleep detection accuracy; wearable technology
- 28 Running title: Verily Study Watch Performance Against PSG
- 29
- 30 Article length: Abstract, 215 (limit 250). Main, ~2156 (limit 4K)

It is made available under a CC-BY-NC-ND 4.0 International license .

31	Disclosures/Acknowledgements page
32	
33	Study funding statement: The study was sponsored by Verily Life Sciences
34 35	<b>Data [/code/materials] sharing statement:</b> Data from this study are not available due to the nature of this program. Participants did not consent for their data to be shared publicly.
36	Authors' disclosures:
37 38	S Saeb, BWN, PB, NV, HA, NS, S Sullivan, SP, ER, RK, S Shin report employment and equity ownership in Verily Life Sciences.
39 40	MDZ, FB and NA received research funding through their institution from Verily Life Sciences for study execution.
41	Authors' contributions:
42	Study concept and design: SSaeb, BWN, SSullivan, MdZ, RK, SShin
43	Data collection: Verily Life Sciences, FCB, NA
44	Data analysis and interpretation: PB, SSaeb
45	Draft writing and review: All
46	Draft approval for submission: All
47	Acknowledgements:
48	Authors wish to acknowledge participants and study personnel that made the study

49 possible.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 50 Abstract

51 **Introduction:** This study evaluated the performance of a wrist-worn wearable, Verily Study

- 52 Watch (VSW), in detecting key sleep measures against polysomnography (PSG). **Methods:** We
- 53 collected data from 41 adults without obstructive sleep apnea or insomnia during a single
- 54 overnight laboratory visit. We evaluated epoch-by-epoch performance for sleep versus wake
- classification, sleep stage classification and duration, total sleep time (TST), wake after sleep
- onset (WASO), sleep onset latency (SOL), sleep efficiency (SE), and number of awakenings
- 57 (NAWK). Performance metrics included sensitivity, specificity, Cohen's kappa, and Bland-
- Altman analyses. Results: Sensitivity and specificity (95% CIs) of sleep versus wake
   classification were 0.97 (0.96, 0.98) and 0.70 (0.66, 0.74), respectively. Cohen's kappa (95%)
- 60 CI) for 4-class stage detection was 0.64 (0.18, 0.82). Most VSW sleep measures had
- 61 proportional bias. The mean bias values (95% CI) were 14.0 minutes (5.55, 23.20) for TST, -
- 62 13.1 minutes (-21.33, -6.21) for WASO, 2.97% (1.25, 4.84) for SE, -1.34 minutes (-7.29, 4.81)
- 63 for SOL, 1.91 minutes (-8.28, 11.98) for *light sleep* duration, 5.24 minutes (-3.35, 14.13) for
- 64 *deep sleep* duration, and 6.39 minutes (-0.68, 13.18) for *REM sleep* duration. Mean and median
- 65 NAWK count differences (95% CI) were 0.05 (-0.42, 0.53) and 0.0 (0.0, 0.0), respectively.
- 66 **Discussion:** Results support applying the VSW to track overnight sleep measures in free-living
- 67 settings. Registered at clinicaltrials.gov (NCT05276362).

It is made available under a CC-BY-NC-ND 4.0 International license .

## 68 Introduction

- 69 Characterizing sleep in a free-living setting provides valuable insights into physical and mental
- 70 health. Changes in sleep may be key in the diagnosis of sleep disorders like insomnia and
- 71 hypersomnia, and are clinically meaningful components for tracking mental and cardiovascular
- health, as well as other conditions (Parish, 2009)(Freeman et al., 2020)(Tobaldini et al.,
- 73 2019)(Young et al., 2008)(Ahmadi et al., 2009)(Hayashino et al., 2010). The gold standard for
- sleep assessment is lab-based polysomnography (PSG). However, PSG is resource intensive,
- challenging to administer and subject to intra- and inter-scorer variability, moreover, availability
- of PSG laboratories may be limited (Norman et al., 2000)(Deutsch et al., 2006). It is also
- impractical for long-term surveillance, and may be prone to artifacts that affect
- representativeness, such as altered sleep patterns due to the novelty of a laboratory, and/or the
- discomfort of the electrode setting (Toussaint et al., 1995). Furthermore, while portable PSG
- tools do exist, they still have limited application in free-living environments or routine clinicalcare.
- 82 Wearable sensors, particularly wrist-worn devices, provide a promising avenue for sleep
- 83 assessment in free-living settings. These devices are widely available, relatively inexpensive,
- 84 comfortable to wear during sleep and include physiological sensors, such as
- 85 photoplethysmogram (PPG) and accelerometer, that can be used for sleep monitoring (Imtiaz,
- 86 2021)(de Zambotti et al., 2024). However, before utilizing wearable-based technology as a
- 87 routine approach to monitor daily sleep, whether for care or for research purposes, it is
- important to conduct performance evaluation of devices and algorithms compared to a gold
- 89 standard reference such as PSG. Furthermore, researchers now know the importance of
- 90 conducting those analytical and clinical evaluations across diverse and representative
- 91 populations, such as participants with different ages or skin tones, to increase confidence in the
- 92 generalizability of the results (Colvonen et al., 2020)(Baumert et al., 2023)(Nelson et al., 2020).
- This study evaluated the performance of the Verily Study Watch (VSW, a wrist-worn wearable)
   to monitor sleep in a diverse cohort of sleepers without obstructive sleep apnea (OSA) or
- 95 elevated insomnia symptoms, by comparing VSW sleep measures against measures obtained
- 96 from PSG-based labels. The VSW classifies every 30-second epoch into 4 sleep-related stages:
- 97 wake, light sleep, deep sleep, and rapid eye movement (REM) sleep. These classifications
- 98 enable the calculation of multiple sleep measures that provide information on the quantity and
- the quality of an individual's overnight sleep. In this study, the measures of interest were: total
- sleep time (TST), wake after sleep onset (WASO), sleep efficiency (SE), sleep onset latency
- 101 (SOL), number of awakenings (NAWK), and duration of each sleep stage. Our main objective
- 102 was to compare epoch-by-epoch VSW- against PSG- derived classification of sleep-versus-
- 103 wake state and of sleep stages. Additionally, we wanted to assess the VSW's accuracy for all
- 104 computed sleep measures (listed above). Finally, we wanted to evaluate any potential variability
- in the performance of the VSW's sleep algorithm across demographic factors such as age, sex,
- 106 body mass index (BMI), skin tone, and arm hair density.

#### 107 Methods

#### 108 Participants

- 109 The basic setup and eligibility for the study have been described elsewhere (Nelson, 2024,
- submitted). Eligible participants were between 18-80 years old, agreed to abstain from any
- 111 drugs or medications that may affect sleep or wakefulness prior to and during the lab visit, and
- did not have identified symptoms of sleep disorders, such as obstructive sleep apnea (OSA,
- 113 defined by OSA 50 score ≥5), or elevated insomnia symptoms (defined by having an insomnia
- severity index (ISI) score  $\geq$  8). The study was approved by the WCG Institutional Review Board
- 115 (20215892), and all participants provided informed consent.
- 116 This study was registered at clinicaltrials.gov (NCT05276362).
- 117

# 118 Data Collection

- 119 For each participant, data were collected during a single overnight stay in a sleep laboratory at a
- single site (SRI; Menlo Park, California), between February 14th and September 1st, 2023.
- 121 Participants slept in comfortable, sound-proof and temperature-controlled bedrooms. Standard
- 122 PSG protocols were used for preparation, recording procedures, and instrument calibration
- 123 (Nelson, 2024, submitted).
- 124

### 125 Study Watch Data

- 126 During their overnight visit, participants wore the VSW on their dominant wrist. This analysis
- 127 was part of a larger study including two devices: the Verily Numetric Watch (VNW) (Nelson,
- 128 2024, submitted), in addition to the VSW. VSW is equipped with two sensors: a green-light PPG
- sensor, and a 3-axis accelerometer. Both sensors had a sampling frequency of 60 Hz (in the
- 130 VNW, the PPG sensor consists of a green light emitter diode and two PPG signal channels and
- the sampling rate of the 3-axis accelerometer is 104 Hz). Using the PPG and accelerometer
- signals, the VSW classifies every 30-second epoch into one of the following 4 classes: *wake*,
- 133 *light sleep, deep sleep, and REM sleep.*
- 134 The sleep stage classification algorithm consisted of a deep convolutional neural network that
- was initially trained using 10,000 nights of data from the Sleep Heart Health Study (SHHS) and
- 136 Multi-Ethnic Study of Atherosclerosis (MESA) public datasets (Sridhar et al., 2020). The
- algorithm was fine-tuned using a smaller dataset collected at SRI, consisting of 30 nights of
- 138 PSG-labeled data.
- 139 The overnight sleep measures, including TST, WASO, SE, SOL, NAWK, and sleep stage
- 140 durations (Supplementary Table 1), for each participant were calculated using the VSW's
- 141 predicted sleep stages, from the time the lights were turned off ("lights-off") to the time lights
- 142 were turned back on ("lights-on"). VSW start time was synced to the Lights Off time recorded on
- 143 PSG to ensure alignment for analysis of simultaneously recorded signals, using procedures
- 144 described elsewhere (Nelson, 2024, submitted) (de Zambotti et al., 2019).
- 145

### 146 **Reference Data**

- 147 Standard laboratory PSG sleep assessment including electroencephalography (EEG),
- submental electromyography and bilateral electrooculography was performed according to the
- American Academy of Sleep Medicine (AASM) guidelines. Leg movement, electrocardiography
- 150 (ECG), respiratory, and oxygen saturation signals were also collected and used to confirm the

- 151 absence of sleep disordered breathing. All recordings were performed using the Compumedics
- 152 Grael<sup>®</sup> HD-PSG system (Compumedics, Abbotsford, Victoria, Australia). Two independent sleep
- 153 scorers labeled every 30-second epoch of the PSG data by one of the following categories:
- 154 wake, N1, N2, N3, REM. Inter-rater reliability (Kappa) between the two scorers was 91%, and 155 discrepancies were resolved by a third scorer.
- 156 For this analysis, PSG stages N1 and N2 were combined into a single *light sleep* category, and 157 PSG N3 was termed deep sleep.
- 158 Similar to VSW, for each participant, the overnight sleep measures for PSG were calculated
- 159 using the sleep scorer's stage labels from lights-off to lights-on.
- 160

#### 161 **Performance Evaluation**

162 Performance evaluation was done based on an existing standardization framework (Menghini et 163 al., 2021).

- 164 We evaluated the epoch-by-epoch performance of VSW's sleep stage classification against
- 165 PSG in two ways: (1) sleep versus wake classification, using sleep as the positive class; and (2)
- 166 4-class (wake, light, deep, REM) sleep stage classification. For the evaluation of sleep vs wake
- 167 classification, we estimated sensitivity, specificity, positive predictive value (PPV), and negative
- 168 predictive value (NPV). We calculated the 95% CI using cluster bootstrapping, and we
- 169 accounted for the clustering of epochs within a participant using logistic mixed-effect regression
- 170 models with the participant as random effect. For the 4-class stage classification, we used
- 171 Cohen's kappa and accuracy along with their 95% bootstrapped Cls. Additionally we evaluated
- 172 performance for each sleep stage by reporting Cohen's Kappa, accuracy, PPV and sensitivity
- 173 using the average method (Menghini et al., 2021). To obtain performance metrics on each sleep 174
- stage, the outcomes were dichotomized to the sleep stage of interest against all others. The 175 average method calculates kappa for each individual participant and then averages out the
- 176
- kappa across all participants with their associated bootstrapped 95% CIs. All analyses were
- 177 confined to the lights-off to lights-on period.
- 178 For evaluating the performance of all overnight sleep measures except NAWK, we performed
- 179 the Bland Altman analysis, estimating the mean bias and lower and upper limits of agreement,
- 180 testing for the assumptions of proportional bias, heteroscedasticity, and normality. For NAWK,
- 181 we estimated the mean and median count difference and linearly weighted Cohen's kappa with
- 182 their 95% Cls.
- 183 Finally, we evaluated all performance metrics across the participant subgroups, including age,
- 184 sex, BMI, skin tone, arm hair index. For subgroups with insufficient number of samples (< 10),
- 185 we did not evaluate the performance.
- 186 All analyses were performed with R version 4.3.1 (2023-06-16).

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 187 Results

- 188 There were 41 adult participants (18 male, age range: 18-78 years) in this study. Participants 189 had a diverse range of skin tones, BMI, and arm hair density (Supplementary Table 2).
- 190 VSW estimated sleep stages for a total of 38,796 epochs with data collected between lights-off191 and lights-on for each participant.
- 192 The sensitivity (95% CI) of the VSW in classifying sleep vs wake was 0.97 (0.96, 0.98),
- specificity (95% CI) was 0.70 (0.66, 0.74), PPV (95% CI) was 0.93 (0.92, 0.95), and NPV (95%
  CI) was 0.83 (0.78, 0.88) (Table 1).
- 195 The accuracy (95% CI) of the VSW sleep algorithm in classifying all 4 sleep stages was 0.78
- (0.58, 0.89), and the kappa (95% CI) was 0.64 (0.18, 0.82) (Table 2). There was variability in
   the performance across different sleep stages, with *light sleep* stage prediction having the
- 198 lowest accuracy (Table 2), as there were instances of confusion between the *light sleep* stage
- 199 and all other stages (Supplementary Table 3).
- 200 Mean bias and 95% CI values for all overnight sleep measures is shown in Table 3. Bland-
- Altman analyses (Figure 1) showed that all measures had significant proportional bias, with the
- VSW overestimating the measures at the lower end of the distribution, and underestimating
- them at the upper end, relative to the PSG. For all overnight sleep measures except the sleep
- stage durations, the assumption of normality was false, and for all measures except SE the assumption of homoscedasticity was true.
- 206 Performance of the VSW metrics across demographic subgroups of age, sex, BMI, skin tone,
- and arm hair density are reported (Supplementary Tables 4 and 5) without formal statistical testing, due to small subgroup sample size.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 209 Discussion

210 The results of this study show the ability of the VSW to capture information related to sleep

211 quantity and quality, as well as the distribution of sleep stages across overnight periods in

212 individuals without OSA or elevated insomnia symptoms. The sensitivity and specificity of the

213 VSW in classifying sleep vs wake were 0.97 and 0.70 respectively, and the Cohen's kappa for

214 the 4-class stage classification was 0.64. This performance supports the application of the VSW

to monitor overnight sleep in free-living settings.

216 As with other wearable sleep-wake detection devices (Pesonen and Kuula, 2018)(de Zambotti

- et al., 2016)(Miller et al., 2022), the sleep algorithm in this study was more likely to miss wake
- 218 than sleep, as reflected in the higher sensitivity relative to specificity, and the positive and
- negative bias values for TST and WASO, respectively. When evaluating the performance of sleep monitoring devices, the AASM has established a range of 'allowable differences', based
- on actigraphy studies conducted in patients with specific sleep disorders (e.g. insomnia)(Smith
- et al., 2018). The 95% CIs of the mean bias estimates for TST, WASO, SOL, and SE measured
- by the VSW were within those allowable difference ranges. However, for the *proportional* mean
- bias estimates, which account for variations in bias over the range of measurement, 95% CIs
- exceeded these thresholds at lower and higher ends of the measurements (Figure 1).
- 226 Nonetheless, applying the AASM standards to these results may require caution. Unlike the
- studies included in the AASM assessment, the present study excluded (via questionnaire)
- 228 participants with symptoms of certain sleep disorders.
- There are a few caveats to consider when interpreting our results. First, data collection for this
- study took place at a sleep laboratory, with standardized study boundaries and settings, such as lights-on/off to define the "in bed' time period when an individual is (in theory) set to sleep. Free-
- 231 lights-on/off to define the in bed time period when an individual is (in theory) set to sleep.
- living environments are more organic and complex, and the generation of sleep measures inthem may require additional layers of data. Following the prior example, defining "in bed" time
- may necessitate additional sensor readings, which then would be integrated into the derivation
- 235 of the measures, particularly sleep stage classification and duration, or SOL.
- Another caveat is that participants in this study were free of sleep-related diagnoses and
- symptoms (such as OSA or heightened insomnia symptoms). Participants with certain clinical
- 238 conditions may manifest different patterns in their biological signals (e.g., pulse rate) and/or
- sleep architecture, which could complicate the sleep stage classification task. Future studies
- should evaluate the performance of VSW in real-world settings and in clinically relevant
- 241 populations such as individuals with sleep disorders.
- In summary, we evaluated the performance of the VSW and its algorithm to classify sleep
  versus wake state and the four different sleep stages in sleepers without OSA or heightened
  insomnia symptoms, as well as a series of measures that illustrate the quantity and quality of
  overnight sleep. The results demonstrate the potential of VSW to classify sleep vs wake states
- and sleep stages and compute overnight sleep measures when compared to gold-standard
- 247 PSG measurements. These findings support further application of the VSW to tracking the
- overnight sleep behaviors in sleepers without OSA or heightened insomnia symptoms in free-
- 249 living settings.

#### 250 References

Ahmadi, N., Shapiro, G. K., Chung, S. A., and Shapiro, C. M. (2009). Clinical diagnosis of sleep
apnea based on single night of polysomnography vs. two nights of polysomnography. *Sleep Breath.* 13, 221–226. doi: 10.1007/s11325-008-0234-2

Baumert, M., Hartmann, S., and Phan, H. (2023). Automatic sleep staging for the young and the
old - Evaluating age bias in deep learning. *Sleep Med.* 107, 18–25. doi:
10.1016/j.sleep.2023.04.002

Colvonen, P. J., DeYoung, P. N., Bosompra, N.-O. A., and Owens, R. L. (2020). Limiting racial
disparities and bias for wearable devices in health science research. *Sleep* 43. doi:
10.1093/sleep/zsaa159

Deutsch, P. A., Simmons, M. S., and Wallace, J. M. (2006). Cost-effectiveness of split-night
 polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome. *J. Clin. Sleep Med.* 2, 145–153. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17557487

de Zambotti, M., Baker, F. C., Willoughby, A. R., Godino, J. G., Wing, D., Patrick, K., et al.
(2016). Measures of sleep and cardiac functioning during sleep using a multi-sensory
commercially-available wristband in adolescents. *Physiol. Behav.* 158, 143–149. doi:
10.1016/i.physbeh.2016.03.006

de Zambotti, M., Cellini, N., Goldstone, A., Colrain, I. M., and Baker, F. C. (2019). Wearable
sleep technology in clinical and research settings. *Med. Sci. Sports Exerc.* 51, 1538–1557. doi:
10.1249/MSS.00000000001947

- de Zambotti, M., Goldstein, C., Cook, J., Menghini, L., Altini, M., Cheng, P., et al. (2024). State
  of the science and recommendations for using wearable technology in sleep and circadian
  research. *Sleep* 47. doi: 10.1093/sleep/zsad325
- Freeman, D., Sheaves, B., Waite, F., Harvey, A. G., and Harrison, P. J. (2020). Sleep
  disturbance and psychiatric disorders. *Lancet Psychiatry* 7, 628–637. doi: 10.1016/S22150366(20)30136-X
- Hayashino, Y., Yamazaki, S., Takegami, M., Nakayama, T., Sokejima, S., and Fukuhara, S.
  (2010). Association between number of comorbid conditions, depression, and sleep quality
  using the Pittsburgh Sleep Quality Index: results from a population-based survey. *Sleep Med.*11. 366–371. doi: 10.1016/j.sleep.2009.05.021
- Imtiaz, S. A. (2021). A Systematic Review of Sensing Technologies for Wearable Sleep Staging.
   Sensors 21. doi: 10.3390/s21051562
- Menghini, L., Cellini, N., Goldstone, A., Baker, F. C., and de Zambotti, M. (2021). A
  standardized framework for testing the performance of sleep-tracking technology: step-by-step
  guidelines and open-source code. *Sleep* 44. doi: 10.1093/sleep/zsaa170
- Miller, D. J., Sargent, C., and Roach, G. D. (2022). A Validation of Six Wearable Devices for
  Estimating Sleep, Heart Rate and Heart Rate Variability in Healthy Adults. *Sensors* 22. doi:
  10.3390/s22166317
- 288 Nelson, B.W., Low, C.A., Jacobson, N. Areán, P., Torous, J., Allen, N. B. (2020). Guidelines for

- wrist-worn consumer wearable assessment of heart rate in biobehavioral research. *NPJ Digit. Med.* 3, 90. https://doi.org/10.1038/s41746-020-0297-4
- Norman, R. G., Pal, I., Stewart, C., Walsleben, J. A., and Rapoport, D. M. (2000). Interobserver
   agreement among sleep scorers from different centers in a large dataset. *Sleep* 23, 901–908.
- 293 Available at: https://www.ncbi.nlm.nih.gov/pubmed/11083599
- Parish, J. M. (2009). Sleep-related problems in common medical conditions. *Chest* 135, 563–
  572. doi: 10.1378/chest.08-0934
- Pesonen, A.-K., and Kuula, L. (2018). The Validity of a New Consumer-Targeted Wrist Device in
  Sleep Measurement: An Overnight Comparison Against Polysomnography in Children and
  Adolescents. J. Clin. Sleep Med. 14, 585–591. doi: 10.5664/jcsm.7050
- Smith, M. T., McCrae, C. S., Cheung, J., Martin, J. L., Harrod, C. G., Heald, J. L., et al. (2018).
  Use of Actigraphy for the Evaluation of Sleep Disorders and Circadian Rhythm Sleep-Wake
  Disorders: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and
- 302 GRADE Assessment. J. Clin. Sleep Med. 14, 1209–1230. doi: 10.5664/jcsm.7228
- Sridhar, N., Shoeb, A., Stephens, P., Kharbouch, A., Shimol, D. B., Burkart, J., et al. (2020).
  Deep learning for automated sleep staging using instantaneous heart rate. *NPJ Digit Med* 3,
  106. doi: 10.1038/s41746-020-0291-x
- 505 100. 001. 10.1050/541740-020-0291-X
- Tobaldini, E., Fiorelli, E. M., Solbiati, M., Costantino, G., Nobili, L., and Montano, N. (2019).
- Short sleep duration and cardiometabolic risk: from pathophysiology to clinical evidence. *Nat. Rev. Cardiol.* 16, 213–224. doi: 10.1038/s41569-018-0109-6
- 309 Toussaint, M., Luthringer, R., Schaltenbrand, N., Carelli, G., Lainey, E., Jacqmin, A., et al.
- (1995). First-night effect in normal subjects and psychiatric inpatients. *Sleep* 18, 463–469. doi:
  10.1093/sleep/18.6.463
- 312 Young, J. S., Bourgeois, J. A., Hilty, D. M., and Hardin, K. A. (2008). Sleep in hospitalized
- medical patients, part 1: factors affecting sleep. J. Hosp. Med. 3, 473–482. doi: 10.1002/jhm.372

It is made available under a CC-BY-NC-ND 4.0 International license .

- 314 Tables
- 315 Table 1. Performance of VSW's sleep vs wake classification against PSG reference.
- 316

	Sensitivity (95% CI)	Specificity (95% CI)	NPV (95% CI)	PPV (95% CI)	
Sleep vs Wake	l 0.97 (0.96, 0.98)	0.70 (0.66, 0.74)	0.83 (0.78, 0.88)	0.93 (0.92, 0.95)	

CI: Confidence Interval; NPV: Negative Predictive Value; PPV: Positive Predictive Value

It is made available under a CC-BY-NC-ND 4.0 International license .

318	Table 2. V	/SW's performan	ce in 4-class slee	p stage detection	on against the P	SG reference.
-----	------------	-----------------	--------------------	-------------------	------------------	---------------

#### 319

Sleep Stage	Карра (95% СІ)	Accuracy (95% CI)	PPV (95% CI)	Sensitivity (95% CI)		
Overall	0.64 (0.18, 0.82)	0.78 (0.58, 0.89)	I NA	NA		
Wake	0.70 (0.43, 0.90)	0.92 (0.76, 0.98)	0.82 (0.51, 0.98)	0.71 (0.45, 0.94)		
Light	0.60 (0.29, 0.78)	0.80 (0.66, 0.89)	0.80 (0.55, 0.91)	0.81 (0.59, 0.94)		
Deep	0.66 (0.17, 0.91)	0.92 (0.84, 0.98)	0.69 (0.09, 0.97)	0.77 (0.37, 0.98)		
REM	0.74 (0.38, 0.90)	0.92 (0.82, 0.98)	0.76 (0.44, 0.96)	0.84 (0.47, 0.99)		

CI: confidence interval; PPV: Positive Predictive Value; REM: Rapid Eye Movement

320

Measure	sure Mean		Assumptions	Propo	Proport. Bias		er LOA	Upper LOA		
	PSG (SD)	VSW (SD)	Bias (95% CI)		Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
TST (min)	384.98 (60.85)	398.98 (49.04)	14.00 (5.55, 23.20)	Prop Bias = T Normality = F Heteroscedastic = F	125.51 + -0.29 x PSG	Intercept = [65.50, 186.28] Slope = [-0.45, - 0.14]	-9.04	[-87.36,18.83]	105.04	[26.76,133.36]
WASO (min)	62.72 (49.97)	49.60 (38.73)	-13.12 (-21.33, -6.21)	Prop Bias = T Normality = F Heteroscedastic = F	7.11 + -0.32 x PSG	Intercept = [-3.68, 15.8] Slope = [-0.51, - 0.10]	bias - 2.46(1.32 + 0.18 x PSG)	Intercept = [-2.91, 6.58] Slope = [0.06, 0.27]	bias + 2.46(1.32 + 0.18 x PSG	Intercept = [-2.91, 6.58], Slope = [0.06, 0.27]
SE (%)	81.69 (11.71)	84.67 (9.01)	2.97 (1.25, 4.84)	Prop Bias = T Normality = F Heteroscedastic = T	30.04 + -0.33 x PSG	Intercept = [14.81, 42.28] Slope = [-0.47, - 0.16]	bias - 2.46(11.98 + -0.11 x PSG)	Intercept = [4.19, 21.56], Slope = [- 0.22, -0.02]	bias + 2.46(11.98 + -0.11 x PSG	Intercept = [4.19, 21.56], Slope = [- 0.22, -0.02]
SOL (min)	25.43 (20.37)	24.09 (19.73)	-1.34 (-7.29, 4.81)	Prop Bias = T Normality = F Heteroscedastic = F	11.7 + -0.51 x PSG	Intercept = [3.28, 21.81] Slope = [-0.86, - 0.15]	-44.21	[-84.21,-7.38]	34.21	[-5.59,70.51]
Light (min)	240.65 (49.27)	242.56 (43.83)	1.91 (-8.28, 11.98)	Prop Bias = T Normality = T Heteroscedastic = F	83.34 + -0.34 x PSG	Intercept = [40.42, 123.65] Slope = [-0.51, - 0.17]	-25.06	[-119.66,-10.10]	107.06	[12.69,122.06]
Deep (min)	63.39 (27.19)	68.62 (20.12)	5.24 (-3.35, 14.13)	Prop Bias = T Normality = T	54.33 + -0.77 x PSG	Intercept = [40.81, 67.44] Slope = [-0.95, -	-72.30	[-97.21,3.10]	39.31	[14.51,114.76]

Table 3. Performance of VSW overnight sleep measures against PSG reference.

				Heteroscedastic = F									
REM (min)	82.49 (25.46	5) 88.88 (23.60)	) 6.39 (-0.68, 13.18)	Prop Bias = T Normality = T	45.69 + -0.48 x PSG	Interce [26.79	ept = , 69.87]	-21.48	[-84.16,-3	3.21]	68.48	[5.91,86	.55]
				Heteroscedastic = F		Slope = 0.24]	= [-0.78, -						
Measure	PSG Mean (SD)	VSW Mean (SD)	Mean Difference (95%	CI)	PS	G Median	VSW Median	Median Differer CI)	nce (95%	Linear W	/eighted Kapp	a (95% CI)	
NAWK (count)	2.17 (1.96)	1.88 (2.31)	0.05 (-0.42, 0.53)		1		1	0.0 (0.0, 0.0)		0.58 (0.4	1, 0.71)		

CI: confidence interval; LOA: Limits of Agreement; NAWK: Night Awakenings; PPV: Positive Predictive Value; PSG: Polysomnography; REM: Rapid Eye Movement; SD: Standard Deviation; SE: Sleep Efficiency; SOL: Sleep Onset Latency; TST: Total Sleep Time; VSW: Verily Study Watch; WASO: Wake After Sleep Onset

Г

It is made available under a CC-BY-NC-ND 4.0 International license .

#### Figure 1.

Bland-Altman plots of overnight sleep measures for the device (VSW) against the reference (PSG). Solid red lines indicate mean bias, dotted red lines indicate 95% CI of mean bias, solid gray lines indicate the 95% LOAs, and dotted gray lines indicate 95% CI of LOAs. Black dots are observations.

(CI: confidence interval; REM: Rapid Eye Movement; SD: Standard Deviation; SE: Sleep Efficiency; SOL: Sleep Onset Latency; TST: Total Sleep Time; WASO: Wake After Sleep Onset)



50 100 Reference REM Duration (min)